Many of our supporters joined Myeloma UK in congratulating myeloma patient Jane, who recently celebrated reaching an important milestone since […]
The purpose of the Myeloma XII trial is to see if using a novel drug called ixazomib (Ninlaro®) can strengthen the effect of a second high-dose therapy and stem cell transplant (HDT-SCT).
Myeloma UK is getting ready to attend the 2017 British Society of Haematology’s (BSH) Annual Scientific Meeting, which this year takes place in Brighton. Monica Morris is our Healthcare Professional Manager and is part of the Myeloma UK team attending the conference, “The BSH Annual Meeting attracts leading haematologists from across the UK to discuss the latest developments, not just in myeloma, but across a number of other haematological areas, and is a great opportunity for haematology doctors and nurses to learn about the latest developments in myeloma treatment and care.”
Myeloma UK is looking to speak to patients with relapsing myeloma who have received a new combination treatment to help provide evidence in favour of the approval of the treatment in Scotland.
The National Institute for Health and Care Excellence (NICE), the drug approval body for England and Wales, has published draft negative guidance for daratumumab (Darzalex®) monotherapy (for use on its own and not in combination with other drugs). This means that, as it stands, it is unlikely to be made available in this setting on the NHS for relapsed and refractory myeloma. Myeloma UK Policy and Public Affairs Manager, Kate Morgan said, “This is a very disappointing decision for myeloma patients in England and Wales, but it was always going to be a challenging appraisal.”
Myeloma UK has launched clinical trial MUK eleven which will open to recruitment imminently. It is a first of its kind immunotherapy trial which aims to encourage the immune system to target myeloma cells.
The Amyloidosis Research Consortium wants to find out more about patients with cardiac AL amyloidosis and their journey to diagnosis, both in the US and other countries.
Findings have been published from the MUK six clinical trial, a trial conducted as part of the Myeloma UK Clinical Trial Network. Myeloma UK Research Director, Simon Ridley, explains how the findings could help myeloma patients in the future.
The SMC decision means that patients in Scotland will not be able to access either of these treatment indications routinely. Myeloma UK Policy and Public Affairs Manager, Kate Morgan commented, “Myeloma UK made a strong case to the SMC for the approval of both indications and we are very disappointed by the decision not to recommend them for use.
Patients now have better access to new medicines for rare cancer thanks to reforms to the drug approval system in Scotland, an independent review has found.